FASN is a key enzyme in the de novo lipogenesis pathway that is responsible for the synthesis of excess fat in the liver of patients with NAFLD and regulated by SREBP-1 and PPAR-γ. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.